Features and Outcomes of Patients With Reactive Arthritis
A Bicentre Retrospective Study of Features and Outcomes of Patients With Reactive Arthritis
1 other identifier
observational
58
1 country
2
Brief Summary
The aim of this study is to assess the incidence and the clinical and therapeutic characteristics of reactive arthritis and to compare them with those of a historical cohort. We hypothesised that improved hygiene together with prevention and treatment of sexually transmitted infections may have decreased the incidence of reactive arthritis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Feb 2013
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2014
CompletedFirst Submitted
Initial submission to the registry
April 19, 2019
CompletedFirst Posted
Study publicly available on registry
April 24, 2019
CompletedApril 24, 2019
April 1, 2019
1.9 years
April 19, 2019
April 23, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
To determine the incidence of reactive arthritis in patients hospitalised in the rheumatology department
Incidence of reactive arthritis in patients hospitalised in the rheumatology department
December 2014
Study Arms (1)
Patient with reactive arthritis
Interventions
The following variables will be retrospectively assessed by medical record review using a standardised data collection form:demographics; gender, age; family or personal history of spondyloarthritis, psoriasis, uveitis, inflammatory bowel disease; clinical presentation; mono, oligo or polyarthritis, dactylitis, inflammatory joint pain, enthesopathy, axial symptoms, fever, extra-articular manifestations (conjunctivitis, anterior uveitis, circinate balanitis, skin rash); time interval between infection and musculoskeletal manifestations; causal microorganism if known, or triggering event; HLA-B27; radiographic sacroiliitis; treatments and outcomes (complete recovery at one year follow-up, relapse within 6 months after onset, or spondyloarthritis according to the ASAS criteria).
Eligibility Criteria
Patients with active reactive arthritis
You may qualify if:
- reactive arthritis diagnosed in one of the two rheumatology departments from Centre Hospitalier Lyon Sud or Besançon
You may not qualify if:
- presence of other known causes of arthritis, such as other defined spondyloarthritides, septic arthritis, Lyme disease, microcrystalline arthritis or rheumatoid arthritis
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
CHU de Besançon
Besançon, France
Centre Hospitalier Lyon Sud
Pierre-Bénite, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Fabienne COURY-LUCAS, MD
Hospices Civils de Lyon
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 19, 2019
First Posted
April 24, 2019
Study Start
February 1, 2013
Primary Completion
December 31, 2014
Study Completion
December 31, 2014
Last Updated
April 24, 2019
Record last verified: 2019-04